This is for Darifenacin extended-release tablets from the United States Food and Drug Administration. Darifenacin extended-release tablets are AB-rated generic equivalents of Allergan’s Enablex tablets, 7.5 mg and 15 mg, and are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.

Cipla receives final approval for its Abbreviated New Drug Application

Leave a Reply

Your email address will not be published. Required fields are marked *